Szela Mary T 4

What Happened
Mary T. Szela, CEO, President and a director of TriSalus Life Sciences, purchased 30,487 shares on February 23, 2026 at $4.10 per share, for a total reported cost of $124,997. This was a purchase (transaction code P), which represents an insider buy rather than a sale.

Key Details

• Transaction date: 2026-02-23. Price: $4.10 per share. Shares acquired: 30,487. Total value: $124,997.
• Transaction code: P — open market or private purchase (as reported).
• Shares owned after transaction: not specified in the provided filing excerpt; see the full Form 4 for total beneficial ownership.
• No 10b5-1 plan, tax‑withholding, or other footnotes were disclosed in the provided data.
• Filing date/accession: 2026-02-23; no late filing indicated from the provided information.

Context
Insider purchases can signal alignment with shareholders because executives are adding to their stake, but they are only one data point and do not prove future company performance. The reported purchase (~$125k) is a direct buy by the CEO; retail investors may view this as a modest insider buy worth noting alongside broader research. For full detail on holdings and any footnotes, consult the complete Form 4 (Accession No. 0001628280-26-010603).